Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma. METHODS: Patients received cabozantinib 100 mg daily during a 12-week...

Descripción completa

Detalles Bibliográficos
Autores principales: Daud, Adil, Kluger, Harriet M, Kurzrock, Razelle, Schimmoller, Frauke, Weitzman, Aaron L, Samuel, Thomas A, Moussa, Ali H, Gordon, Michael S, Shapiro, Geoffrey I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318966/
https://www.ncbi.nlm.nih.gov/pubmed/28103611
http://dx.doi.org/10.1038/bjc.2016.419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318966/
https://www.ncbi.nlm.nih.gov/pubmed/28103611
http://dx.doi.org/10.1038/bjc.2016.419

Ejemplares similares